MicroRNA cluster 221-222 and estrogen receptor α interactions in breast cancer

Journal of the National Cancer Institute

Volumn 102, Issue 10, 2010, Pages 706-721

  Di Leva, Gianpiero ^a   Gasparini, Pierluigi ^a   Piovan, Claudia ^b   Ngankeu, Apollinaire ^a   Garofalo, Michela ^a   Taccioli, Cristian ^a   Iorio, Marilena V ^b   Li, Meng ^c   Volinia, Stefano ^a   Alder, Hansjuerg ^a   Nakamura, Tatsuya ^a   Nuovo, Gerard ^a   Liu, Yunlong ^c   Nephew, Kenneth P ^c   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; LUCIFERASE; MICRORNA; RETINOIC ACID; SCATTER FACTOR RECEPTOR; THYROID HORMONE RECEPTOR;

ARTICLE; BREAST CANCER; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HYPOTHESIS; IMMUNOPRECIPITATION; NORTHERN BLOTTING; PRIORITY JOURNAL; RNA TRANSCRIPTION;

BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; PLASMIDS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 77952921840     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq102     Document Type: Article

References (45)

1. Elledge RM, Allred DC. Clinical aspect of estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Disease of the Breast. Philadelphia, PA: Lippincott Williams and Wilkins; 2004:601-617.
2. Allred DC, Brown P, Medina D. The origin of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004;6(6):240-245.
3. Santen RJ, Song RX, McPherson R, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002;80(2):239-256.
4. Stoner M, Saville B, Wormke M, et al. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol Endocrinol. 2002;16(10):2231-2242. (Pubitemid 35155536)
5. Oh AS, Lorant LA, Holloway JN, et al. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol. 2001;15(8):1344-1359.
6. Yan L, Yang X, Davidson NE. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia. 2001;6(2):183-192.
7. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006): 350-355.
8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-866.
9. Iorio MV, Ferracin M, Veronese A, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065-7070.
10. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 2007;21(5):1132-1147.
11. Zhao JJ, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008;283(45):31079-31086.
12. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283(44):29897-29903.
13. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple to multiple testing. J R Stat Soc Ser B. 1995;57(2):289-300.
14. Alter O, Brown PO, Botstein D. Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci USA. 2000;97(18):10101-10106.
15. Draghici S, Khatri P, Tarca AL, et al. A systems biology approach for pathway level analysis. Genome Res. 2007;17(10):1537-1545.
16. Kondo N, Toyama T, Sugiura H, et al. miR-206 Expression is downregu-lated in estrogen receptor alpha-positive human breast cancer. Cancer Res. 2008;68(13):5004-5008.
17. Le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26(15):3699-3708.
18. Lee SW, Reimer CL, Oh P, et al. Tumor cell growth inhibition by caveo-lin re-expression in human breast cancer cells. Oncogene. 1998;16(11): 1391-1397.
19. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6(3):184-192.
20. Musgrove EA, Davidson EA, Ormandy CJ. Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice. J Mammary Gland Biol Neoplasia. 2004;9(1):55-66.
21. Kang MH, Reynolds CP. Bcl2 inhibitors: targeting mitochondrial apo-ptotic pathways in cancer therapy. Clin Cancer Res. 2009;15(4): 1126-1132.
22. Mak BC, Yeung RS. The tuberous sclerosis complex genes in tumor development. Cancer Invest. 2004;22(4):588-603.
23. Yang JY, Hung MC. A new fork for clinical application: targeting fork-head transcription factors in cancer. Clin Cancer Res. 2009;15(3): 752-757.
24. Terasaka K, Ichimura A, Sato F, Shimizu K, Tsujimoto G. Sustained activation of ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells. FEBS J. 2009;276(12):3269-3276.
25. Alarmo EL, Kuukasjarvi T, Karhu R, Kallioniemi A. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat. 2007;103(2): 239-246.
26. Katsuno Y, Hanyu A, Kanda H, et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through SMAD pathway. Oncogene. 2008;27(49):6322-6333.
27. Kim HK, Lee YS, Sivaprasad U, et al. Muscle-specifc microRNA miR-206 promotes muscle differentiation. J Cell Biol. 2006;174(5):677-687.
28. Graveel CR, DeGroot JD, Su Y, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA. 2009;106(31):12909-12914.
29. Stahl M, Dijkers PF, Kops GJ, et al. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol. 2002;168(10):5024-5031.
30. Chandramohan V, Mineva ND, Burke B, et al. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor. J Cell Biochem. 2008;104(6):2091-2106.
31. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 2006;66(7):3903-3911.
32. Sainsbury JR, Farndon JR, Sherbet GV, Harris AL. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet. 1985;1(8425):364-366.
33. Giani C, Casalini P, Pupa SM, et al. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene. 1998;17(4):425-432.
34. Gregory RI, Yan KP, Amuthan G, et al. The microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432(7014):235-240.
35. Lonard DM, O'malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell. 2007;27(5):691-700.
36. Minucci S, Nervi C. Lo Coco F, Pelicci PG. Histone deacetylase: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene. 2001;20(24):3110-3115.
37. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24(50):7410-7425.
38. To CT, Tsao MS. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancer. Oncol Rep. 1998;5(5):1013-1024.
39. Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 down-regulation. Cancer Cell. 2009;16(6):498-509.
40. Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 2010;107(1): 264-269.
41. Stossi F, Likhite VS, Katzenellenbogen JA, et al. Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter. J Biol Chem. 2006;281(24): 16272-16278.
42. Higgins KJ, Liu S, Abdelrahim M, et al. Vascular endothelial growth factor receptor-2 expression is downregulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins. Mol Endocrinol. 2008;22(2):388-402.
43. Adams BD, Cowee DM, White BA. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF7 breast cancer cells. Mol Endocrinol. 2009;23(8):1215-1230.
44. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27(43):5651-5661.
45. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008;27(27):3845- 3855.